|
or fast descent to 44 depending on denosomab feedback from FDA. If FDA follows advisory panel then look for real long delay on the remaining two indications.
This stock is too risky at this stage. Rating :
 (1 Rating) |
Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.01